<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the treatment of renal cell carcinoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the treatment of renal cell carcinoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the treatment of renal cell carcinoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 05, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1726796296">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma (Wilms tumor) is common in children (5 to 6 percent of pediatric malignancies). (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2987.html" rel="external">
          "Malignancies of the renal pelvis and ureter"
         </a>
         .)
        </p>
        <p>
         An overview of the approach to treatment is presented here; more detailed discussions of specific aspects of treatment are discussed in other topics, as noted below.
        </p>
        <p class="headingAnchor" id="H1353149290">
         <span class="h1">
          GENERAL APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial approach to a patient with presumed RCC needs to consider the extent of disease, as well as the patient's age and comorbidity  (
         <a class="graphic graphic_algorithm graphicRef109427" href="/z/d/graphic/109427.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         RCC can be classified as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Localized disease
         </strong>
         – This includes stage I, II, and III  (
         <a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Localized renal cell carcinoma'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advanced disease
         </strong>
         – This includes tumor invading beyond Gerota's fascia or extending into the ipsilateral adrenal gland (T4) and metastatic disease (M1). Either of these findings constitutes stage IV RCC. (See
         <a class="local">
          'Advanced renal cell carcinoma'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         An overview of the approach to treatment is presented here; more detailed discussions of specific aspects of treatment are discussed in other topics, as noted below.
        </p>
        <p class="headingAnchor" id="H1056311476">
         <span class="h1">
          LOCALIZED RENAL CELL CARCINOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         When patients with RCC present with localized disease, definitive therapy can often be curative.
        </p>
        <p class="headingAnchor" id="H1056311484">
         <span class="h2">
          Definitive treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgery is curative in the majority of patients with RCC who do not have metastases. Surgery is therefore the preferred treatment for patients with stages I, II, and III disease.
        </p>
        <p>
         Treatment may require a radical nephrectomy, although a partial nephrectomy to preserve renal parenchyma is preferred for appropriately selected patients. The choice of surgical procedure depends upon the extent of disease, as well as patient-specific factors such as age and comorbidity. Surgery may be carried out through a conventional approach or by a minimally invasive approach such as laparoscopy. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
         In carefully selected patients who present with a resectable primary tumor and a concurrent single metastasis, surgical resection of the metastasis, in conjunction with radical nephrectomy, may be curative. (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
         Other ablative procedures (eg, cryotherapy, radiofrequency ablation [RFA]) may be an important alternative for patients with relatively small renal masses who are not surgical candidates. (See
         <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">
          "Diagnostic approach, differential diagnosis, and management of a small renal mass"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1061468542">
         <span class="h2">
          Multiple primary renal cell carcinomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bilateral RCCs are more common among patients with inherited conditions (eg, von Hippel-Lindau [VHL] disease, tuberous sclerosis, papillary RCC) and occasionally are seen in those with sporadic tumors. In these situations, we recommend surgery. Proper management should include sparing as much renal parenchyma as possible during the initial therapy and monitoring for the development of additional RCCs. (See
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Partial nephrectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056313976">
         <span class="h2">
          Active surveillance in nonsurgical candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Older adult patients and those with significant comorbidity may not be candidates for surgical resection [
         <a href="#rid1">
          1
         </a>
         ]. Although nonsurgical procedures (eg, cryoablation, RFA) may be useful, most small tumors grow slowly and do not become symptomatic or metastasize [
         <a href="#rid2">
          2-6
         </a>
         ]. In addition, up to 40 percent of tumors smaller than 1 cm in size may be benign [
         <a href="#rid7">
          7
         </a>
         ]. In this setting, observation with periodic reevaluation is a reasonable option. (See
         <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">
          "Diagnostic approach, differential diagnosis, and management of a small renal mass"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056313897">
         <span class="h2">
          Adjuvant therapy for locoregional disease
         </span>
        </p>
        <p class="headingAnchor" id="H1637523647">
         <span class="h3">
          Approach to adjuvant therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to adjuvant therapy in patients with locoregionally advanced clear cell renal carcinoma treated with nephrectomy is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who meet pathologic criteria for intermediate-high or high risk of disease recurrence, particularly those with a higher estimated risk of recurrence at five years (≥30 percent), we suggest one year of adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         rather than observation, as this approach improved disease-free survival (DFS) and was well tolerated in a phase III trial [
         <a href="#rid8">
          8,9
         </a>
         ]. The risk of recurrence can be calculated using either the University of California, Los Angeles (UCLA) Integrated Staging System (UISS) (
         <a class="calc calc_professional" href="/z/d/html/140668.html" rel="external">
          calculator 1
         </a>
         ) [
         <a href="#rid10">
          10,11
         </a>
         ] or the Mayo Clinic Leibovich prognostic model [
         <a href="#rid12">
          12,13
         </a>
         ]. (See
         <a class="local">
          'Pembrolizumab'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2961.html" rel="external">
          "Prognostic factors in patients with renal cell carcinoma", section on 'Clinical factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, observation remains a reasonable alternative in this patient population, as further follow-up data are necessary to confirm a long-term OS benefit with adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         and distinguish whether this agent improves DFS because it truly prevents relapse (ie, cures disease) or simply delays relapse. (See
         <a class="local">
          'Pembrolizumab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We offer active surveillance after nephrectomy to patients who are at lower risk for disease recurrence (&lt;30 percent) [
         <a href="#rid10">
          10,12
         </a>
         ] or do not meet pathologic criteria for intermediate-high or high risk of disease recurrence. (See
         <a class="local">
          'Pembrolizumab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We do not suggest the use of adjuvant
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . Although adjuvant sunitinib improved DFS in select patients with high-risk disease in one clinical trial, it confers no clear overall survival (OS) benefit and increases toxicity. (See
         <a class="local">
          'Sunitinib'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For completely resected oligometastatic disease, the role of adjuvant therapy is discussed below. (See
         <a class="local">
          'Adjuvant therapy after metastasectomy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3935308361">
         <span class="h3">
          Pembrolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a double-blind, placebo-controlled phase III trial (KEYNOTE-564), 994 patients with histologically confirmed clear cell renal carcinoma treated with nephrectomy were randomly assigned to either
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         200 mg every three weeks for up to one year (17 cycles) or placebo [
         <a href="#rid8">
          8,9
         </a>
         ]. Patients initiated adjuvant therapy within 12 weeks of undergoing nephrectomy.
        </p>
        <p>
         Risk for disease recurrence was defined as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intermediate-high risk
         </strong>
         – pT2 tumors with grade 4 or sarcomatoid features; or pT3, any grade, and node negative tumors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High risk
         </strong>
         – pT4, any grade, node negative tumors; or any pT, any grade, node positive tumors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastatic, no evidence of disease
         </strong>
         – resection of all oligometastatic sites (M1) with no evidence of disease (NED) within one year of nephrectomy.
        </p>
        <p>
        </p>
        <p>
         At median follow-up of 30 months,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         improved DFS compared with placebo in the entire study population (30-month DFS 75 versus 66 percent, HR 0.63, 95% CI 0.50-0.80) and those with intermediate-high tumors (median not reached for both treatments, HR 0.68, 95% CI 0.52-0.89). For the subgroup of 76 patients with high-risk tumors, median DFS for pembrolizumab versus placebo were 22 and 11 months, respectively (HR 0.60, 95% CI 0.33-1.10) [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         Adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         also demonstrated higher OS in the entire study population (30-month OS 96 versus 91 percent, HR 0.52, 95% CI 0.31-0.86); however, OS differences are not statistically significant, and these results are immature pending longer follow-up. Grade ≥3 toxicity rates were higher with pembrolizumab than placebo (32 versus 18 percent), with no new toxicity profiles noted.
        </p>
        <p>
         Based on these data, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) granted regulatory approval for
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Further data on the efficacy of adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in patients who underwent metastasectomy are discussed below. (See
         <a class="local">
          'Adjuvant therapy after metastasectomy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H612568669">
         <span class="h3">
          Sunitinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         is approved by the FDA for adjuvant therapy based on improved DFS in patients with high-risk disease, it has not shown an OS benefit in any subgroup and is associated with toxicities. Clinical trials evaluating other targeted agents, such as sunitinib and
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         (ASSURE and SORCE),
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         (PROTECT), and
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         (ATLAS), have also failed to demonstrate a recurrence-free or OS benefit in the adjuvant setting [
         <a href="#rid15">
          15-20
         </a>
         ]. As such, we do not suggest adjuvant use of any of these agents for RCC. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Preferred VEGFR inhibitors'
         </a>
         .)
        </p>
        <p>
         Further details of these trials are discussed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the phase III ASSURE trial, 1943 patients with completely resected intermediate-, high-, or very high-risk RCC were randomly assigned to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         , or placebo for up to one year [
         <a href="#rid16">
          16
         </a>
         ]. After a median follow-up of 5.8 years, results demonstrated the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar DFS results for each of the treatment arms (for
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         versus placebo, median 5.8 versus 6.6 years, hazard ratio [HR] 1.02, 97.5% CI 0.85-1.23; for
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         versus placebo, median 6.1 versus 6.6 years, HR 0.97, 97.5% CI 0.8-1.17).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar OS for each of the treatment arms (for
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         versus placebo, HR 1.17, 97.5% CI 0.9-1.52; for
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         versus placebo, HR 0.98, 97.5% CI 0.75-1.28). Older women also experienced increased mortality in a post-hoc subgroup analysis [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Higher grade 3 or greater toxicities with both
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         and
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         compared with placebo (hypertension 17 and 16 versus 4 percent, hand-foot syndrome 15 and 33 versus 1 percent, rash 2 and 15 versus &lt;1 percent, and fatigue 18 and 7 versus 3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the phase III S-TRAC trial, 615 patients with high-risk clear cell RCC were randomly assigned to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         or placebo [
         <a href="#rid15">
          15
         </a>
         ]. At a median follow-up of 5.4 years, DFS (the primary endpoint) was significantly increased in those receiving sunitinib (median 6.8 versus 5.6 years, 59.3 versus 51.3 percent five-year DFS, HR 0.76, 95% CI 0.59-0.95). OS data were immature, although the number of deaths was equal among the treatment arms. Toxicity was increased significantly with sunitinib compared with placebo, including palmar-plantar erythrodysesthesia and hypertension.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3545930253">
         <span class="h3">
          Other agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following agents either have failed to demonstrate a clear clinical benefit in the adjuvant setting or are under investigation in clinical trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapy
         </strong>
         – In phase III trials,
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ] failed to improve DFS in the adjuvant setting, and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         failed to improve recurrence-free survival in the perioperative setting [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a phase III trial (Checkmate 914), adjuvant
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         also failed to improve DFS in the entire study population [
         <a href="#rid23">
          23
         </a>
         ]. However, in preliminary results from a subgroup analysis, DFS benefit was seen among patients who had tumors with sarcomatoid features (HR 0.29), Furman grade IV disease (HR 0.72), or PD-L1 expression ≥1 percent (HR 0.40) [
         <a href="#rid24">
          24
         </a>
         ]. The use of adjuvant nivolumab plus ipilimumab for these subgroups remains investigational pending regulatory approval and/or incorporation into clinical guidelines. (See
         <a class="medical medical_review" href="/z/d/html/128561.html" rel="external">
          "Renal cell carcinoma with sarcomatoid features"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other clinical trials are comparing alternative immunotherapy agents with placebo (see
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Selection of initial therapy'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">
          Durvalumab
         </a>
         with or without
         <a class="drug drug_general" data-topicid="139983" href="/z/d/drug information/139983.html" rel="external">
          tremelimumab
         </a>
         (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03288532&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPODeRc5KQ4dTyxFKbFn%2FY%2FeDjSA6jzJJgXftbJSxWUDZw%3D%3D&amp;TOPIC_ID=15719" target="_blank">
          NCT03288532
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pazopanib
         </strong>
         – In a phase III trial (PROTECT) of 1538 patients with completely resected RCC,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         (at a lower dose of 600 mg daily) did not improve DFS or OS compared with placebo [
         <a href="#rid18">
          18,25
         </a>
         ]. However, DFS was improved for those assigned to a higher (800 mg daily) dosing (66 versus 56 percent, HR 0.66, 95% CI 0.49-0.9).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Axitinib
         </strong>
         – In a phase III randomized, double-blind, placebo-controlled trial (ATLAS) conducted in 724 patients with localized RCC status post nephrectomy,
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         failed to demonstrate a DFS advantage in the total study population [
         <a href="#rid19">
          19
         </a>
         ]. OS data were not mature. Grade 3 or greater toxicities were more frequent in the axitinib arm (61 versus 30 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sorafenib
         </strong>
         <strong>
         </strong>
         – In a phase III trial (SORCE) conducted in 1711 patients with completely resected RCC at intermediate or high risk of disease recurrence,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         did not improve DFS or OS and increased toxicity, compared with placebo [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Girentuximab
         </strong>
         –
         <strong>
         </strong>
         Another large phase III trial using girentuximab (an antibody targeting carbonic anhydrase IX) failed to demonstrate any benefit in either DFS or OS [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Everolimus
         </strong>
         – In a phase III trial (EVEREST) of 1545 patients with resected non-metastatic RCC (including both clear cell and non-clear cell histologies), adjuvant therapy with
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         failed to improve recurrence-free survival (RFS) or OS compared with placebo and resulted in high rates of treatment discontinuation due to toxicity [
         <a href="#rid27">
          27
         </a>
         ]. However, RFS was improved among those at very high risk of disease recurrence (five-year RFS 57 versus 51 percent, HR 0.79, 95% CI 0.65-0.97), suggesting potential efficacy in this population.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1525133897">
         <span class="h2">
          Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful surveillance after definitive treatment is important to permit early diagnosis of relapse when the tumor burden is limited. The response to therapy of patients who relapse is best in patients with a good performance status and a limited tumor burden. Furthermore, some patients who have a solitary recurrence may be cured with surgical metastasectomy. (See
         <a class="medical medical_review" href="/z/d/html/2969.html" rel="external">
          "Surveillance for metastatic disease after definitive treatment for renal cell carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056314147">
         <span class="h1">
          ADVANCED RENAL CELL CARCINOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many RCCs are clinically silent for much of their natural history. Thus, the diagnosis is frequently not made until disease is locally advanced (and unresectable) or has metastasized. In addition, many patients who initially are resectable eventually recur. Systemic therapy (immunotherapy, molecularly targeted agents), surgery, and radiation therapy (RT) all may have a role depending on the extent of disease, sites of involvement, and patient-specific factors.
        </p>
        <p>
         The general treatment approach to clear cell RCC is discussed below. The treatment approach to non-clear cell RCC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2292316449">
         <span class="h2">
          General treatment approach
         </span>
        </p>
        <p class="headingAnchor" id="H2423528735">
         <span class="h3">
          Clear cell renal cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment-naïve patients with advanced or metastatic disease not controlled by definitive locoregional therapy receive systemic treatment with immunotherapy (checkpoint inhibitors) and/or molecularly targeted/antiangiogenic therapy  (
         <a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">
          algorithm 2
         </a>
         ). Systemic therapy is initiated promptly in most patients with substantial disease burden. Active surveillance may be offered to asymptomatic patients with favorable-risk disease and limited disease burden to determine disease tempo. Patients should be encouraged to participate in formal clinical trials whenever possible. The approach to initial and subsequent systemic therapy in patients with advanced or metastatic RCC is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma"
         </a>
         .)
        </p>
        <p>
         The choice of treatment for patients with advanced disease has been based on prognostic risk factors historically developed in the era of frontline vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs).
        </p>
        <p>
         The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model integrates six adverse factors and stratifies patients into favorable-, intermediate-, or poor-risk groups  (
         <a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The relevance of the IMDC prognostic criteria in the era of frontline combination immunotherapy remains to be established. In the absence of alternative immunotherapy-based prognostic criteria, these criteria continue to be used in clinical trials to risk-stratify patients and, to some extent, by providers and clinical guidelines to direct therapy. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Risk stratification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2909872049">
         <span class="h3">
          Non-clear cell renal cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment approach to patients with metastatic non-clear cell RCC is varied and, to some extent, tailored to the histologic subtype and pathologic and molecular features of the tumor. The main histologic subtypes of non-clear cell RCC include papillary, chromophobe, collecting duct (including medullary carcinoma), translocation, and unclassified. Although many advances have been made in the treatment of metastatic non-clear cell RCC, there are limited high-quality data to help inform management, due to the infrequency of these tumors. Details regarding the various treatment approaches for non-clear cell RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H459457554">
         <span class="h3">
          Renal cell carcinoma with sarcomatoid features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal cell carcinoma with sarcomatoid features, or sarcomatoid RCC, is not considered a distinct subtype of RCC because sarcomatoid features can be seen in any histologic subtype of RCC, including both clear cell and non-clear cell histologies. Advanced or metastatic sarcomatoid RCC is clinically responsive to immunotherapy-based regimens. Further details on the management of sarcomatoid RCCs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128561.html" rel="external">
          "Renal cell carcinoma with sarcomatoid features"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2551565429">
         <span class="h2">
          Treatment options
         </span>
        </p>
        <p class="headingAnchor" id="H1056314219">
         <span class="h3">
          Immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunotherapy is an important option for the management of patients with advanced clear cell RCC, both as initial therapy or as subsequent therapy after molecularly targeted/antiangiogenic therapy. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">
          "Principles of cancer immunotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1948108749">
         <span class="h4">
          Checkpoint inhibitor immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Checkpoint inhibition targeting either the programmed cell death receptor 1 (PD-1) pathway and/or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has represented an important advance in the treatment of multiple malignancies, including clear cell RCC.
        </p>
        <p>
         The combination of
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         (an anti-PD-1 antibody) and
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (an anti-CTLA-4 antibody)  (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 3
         </a>
         ) has an established role in the treatment of intermediate- and poor-risk patients [
         <a href="#rid29">
          29,30
         </a>
         ]. Single-agent nivolumab also demonstrated an overall survival (OS) benefit in patients who had progressed after initial antiangiogenic treatment [
         <a href="#rid31">
          31,32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus ipilimumab'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1662587110">
         <span class="h4">
          Combined immunotherapy plus antiangiogenic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combinations of immunotherapy plus antiangiogenic therapy are active in patients with advanced or metastatic RCC. Examples of such combination with OS benefit include
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus pembrolizumab. Another available combination is
         <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">
          avelumab
         </a>
         plus axitinib. Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Initial treatment options'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1853301663">
         <span class="h4">
          Interleukin 2
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunotherapy with high-dose bolus IL-2 can activate an immune response against RCC that results in tumor regression in a minority of patients. Although treatment is associated with severe toxicity, responses often persist for many years, even in the absence of additional therapy, and the majority of complete responders remain free of relapse long term.
        </p>
        <p>
         While high-dose IL-2 was considered an important option for carefully selected patients who are able to tolerate the toxicity associated with this approach and who have access to this treatment, its role in the setting of more active and better tolerated checkpoint inhibitor immunotherapy approaches is undefined. IL-2 still could be an option in patients whose disease has progressed on initial immunotherapy-based regimens. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Interleukin 2 and other interleukins'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056314281">
         <span class="h3">
          Molecularly targeted therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An understanding of the pathogenesis of RCC at the molecular level has identified the vascular endothelial growth factor (VEGF) pathway and mechanistic (mammalian) target of rapamycin (mTOR) as important targets for therapeutic intervention. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Molecular pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056311533">
         <span class="h4">
          Antiangiogenic (VEGF pathway)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two different approaches have clinical activity in blocking the vascular endothelial growth factor (VEGF) pathway  (
         <a class="graphic graphic_figure graphicRef65979" href="/z/d/graphic/65979.html" rel="external">
          figure 1
         </a>
         ): the use of small-molecule TKIs (eg,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">
          tivozanib
         </a>
         ) to block the intracellular domain of the VEGFR, and the use of a monoclonal antibody (
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ) to bind circulating VEGF and prevent it from activating the VEGFR [
         <a href="#rid33">
          33
         </a>
         ]. VEGF inhibitors prolong progression-free survival compared with IFNa for the initial management of advanced RCC. Further data on the activity of these VEGF TKIs in patients with advanced or metastatic clear cell RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Preferred VEGFR inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4069893881">
         <span class="h4">
          Belzutifan
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">
          Belzutifan
         </a>
         , a small molecule inhibitor of hypoxia-inducible factor-2 alpha (HIF-2a), is an option for patients with treatment-refractory advanced or metastatic clear cell renal carcinoma. Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Belzutifan'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">
          Belzutifan
         </a>
         is also used to treat specific von Hippel-Lindau (VHL) disease-related tumors, including RCC. (See
         <a class="local">
          'von Hippel-Lindau disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1056314296">
         <span class="h4">
          mTOR inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanistic (mammalian) target of rapamycin (mTOR) pathway is downstream of the phosphoinositide 3-kinase and Akt pathway that is regulated by the phosphatase and tensin homolog (
         <em>
          PTEN
         </em>
         ) tumor suppressor gene  (
         <a class="graphic graphic_figure graphicRef65979" href="/z/d/graphic/65979.html" rel="external">
          figure 1
         </a>
         ). Inhibition of the mTOR pathway has the potential to inhibit tumor progression at multiple levels. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Inhibitors of the mTOR pathway'
         </a>
         .)
        </p>
        <p>
         However, mTOR inhibitors have a limited role as single agents in advanced RCC. Their principal utility may be in patients whose disease is refractory to initial treatment with VEGFR TKIs and/or those patients whose tumors have mutations in the PI3K pathway. Except for this, their use is relegated to third- or greater-line therapy in patients whose disease has progressed on combination checkpoint inhibitor immunotherapy regimens and
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Temsirolimus
         </strong>
         – In the four-armed phase II BEST trial of patients who had not received prior targeted therapy,
         <a class="drug drug_general" data-topicid="10344" href="/z/d/drug information/10344.html" rel="external">
          temsirolimus
         </a>
         plus either
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         had a worse therapeutic index than either bevacizumab alone or the combination of bevacizumab plus sorafenib [
         <a href="#rid34">
          34
         </a>
         ]. In the INTORSECT trial in patients who had previously been treated with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , OS was significantly worse than with sorafenib [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Bevacizumab plus interferon alfa'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Temsirolimus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Everolimus
         </strong>
         – In the RECORD-3 trial,
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         was inferior to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         as first-line therapy with advanced RCC [
         <a href="#rid36">
          36
         </a>
         ]. In phase III trials in previously treated patients, everolimus was inferior to both
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         [
         <a href="#rid31">
          31
         </a>
         ] and
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Everolimus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2582328022">
         <span class="h3">
          Chemotherapy and hormonal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both chemotherapy and progestational agents had only very limited activity in early studies prior to the development of immunotherapy and molecularly targeted therapy [
         <a href="#rid38">
          38-41
         </a>
         ]. The role of chemotherapy is limited to the use of platinum-based chemotherapy in patients with non-clear cell collecting duct and renal medullary carcinomas. (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma", section on 'Collecting duct and renal medullary carcinoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H471565464">
         <span class="h3">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with stage IV RCC have unresectable disease and require systemic therapy. However, surgery has a role in the management of some patients.
        </p>
        <p class="headingAnchor" id="H471565470">
         <span class="h4">
          Radical nephrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For a subset of patients in whom the only evidence of advanced disease is the direct involvement of the ipsilateral adrenal gland, a radical nephrectomy that includes adrenalectomy is potentially curative. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Adrenal gland involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H471565488">
         <span class="h4">
          Cytoreductive nephrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Removal of the primary tumor (cytoreductive or debulking nephrectomy) may be indicated prior to initiating systemic therapy in select patients (eg, good performance status, 75 percent debulking possible, no symptomatic metastatic disease). (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma", section on 'Cytoreductive nephrectomy'
         </a>
         .)
        </p>
        <p>
         The role of cytoreductive nephrectomy among patients treated with molecularly targeted agents is less promising. This approach is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma", section on 'Antiangiogenic therapy and immune checkpoint inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H471565532">
         <span class="h4">
          Metastasectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical resection of a single or limited number of metastases is a reasonable option for carefully selected patients. This occasionally is done in conjunction with a radical nephrectomy but may also be performed following a relapse after surgery. In addition, surgery is sometimes performed to resect residual disease in patients who have had a major but less than complete response to systemic immunotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">
          "Surgical resection of pulmonary metastases: Outcomes by histology", section on 'Renal cell carcinoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1014654679">
         <span class="h4">
          Adjuvant therapy after metastasectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with completed resected oligometastatic clear cell renal carcinoma treated with nephrectomy and complete resection of all distant disease, we suggest one year of adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         rather than observation, as this approach improved disease-free survival (DFS) in a phase III trial [
         <a href="#rid8">
          8,9
         </a>
         ]. By contrast, adjuvant therapy using VEGF inhibitors does not confer a survival benefit in this setting.
        </p>
        <p>
         The use of adjuvant therapy after surgical resection of locoregionally advanced RCC is discussed separately. (See
         <a class="local">
          'Adjuvant therapy for locoregional disease'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pembrolizumab
         </strong>
         <strong>
         </strong>
         – Adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         was evaluated in a randomized, double-blind, placebo-controlled phase III trial (KEYNOTE-564) of 994 patients with clear cell renal carcinoma who had undergone nephrectomy [
         <a href="#rid8">
          8,9
         </a>
         ]. This study included a subgroup of 58 patients with oligometastatic disease that was completely resected with no evidence of disease (NED) within one year of nephrectomy (M1, NED). In this subgroup of patients, adjuvant pembrolizumab improved DFS (median not reached versus 12 months, HR 0.28, 95% CI 0.12-0.66) versus placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Based on these data the US Food and Drug Administration (FDA) granted regulatory approval for
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or with following nephrectomy and resection of metastatic lesions [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further results of this trial in patients without oligometastatic disease are discussed above. (See
         <a class="local">
          'Adjuvant therapy for locoregional disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other agents
         </strong>
         – Other trials have not demonstrated survival benefit for adjuvant VEGF inhibition in the oligometastatic setting. For example, in a double-blind phase III trial (ECOG-ACRIN E2810), among 129 patients with RCC who were disease free after metastasectomy,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         resulted in a similar disease-free survival (DFS) relative to placebo (median DFS 17.3 versus 14.2 months, hazard ratio [HR] 0.85, 95% CI 0.55-1.31) and worsened OS (HR 2.65, 95% CI 1.02-6.9) [
         <a href="#rid42">
          42
         </a>
         ]. Reported toxicities for pazopanib included fatigue, diarrhea, hypertension, and transaminitis, and one patient died of intracranial hemorrhage. Similarly,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         also failed to demonstrate improvement in recurrence-free survival in a randomized phase II trial conducted in a similar patient population [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Immunotherapy agents under clinical trial evaluation after metastasectomy include
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in KEYNOTE-564 (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03142334&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSz9wsRalc77CFv9OFo%2BGIinsOArAe0XGhOGGJiP1V8J9Q%3D%3D&amp;TOPIC_ID=15719" target="_blank">
          NCT03142334
         </a>
         ) and
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         in IMmotion101 (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03024996&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSz9wsRalc77CFv9OFo%2BGIinJUkOupkleCBp88GZRr%2FEng%3D%3D&amp;TOPIC_ID=15719" target="_blank">
          NCT03024996
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1056311597">
         <span class="h3">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although RCC has been characterized as a radioresistant tumor, conventional and stereotactic RT are frequently useful to treat a single or limited number of metastases [
         <a href="#rid44">
          44
         </a>
         ]. In these settings, the utility of RT is similar to that in metastases from other tumor types.
        </p>
        <p>
         Examples of situations where RT is useful include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Painful bone metastases (see
         <a class="medical medical_review" href="/z/d/html/2805.html" rel="external">
          "Radiation therapy for the management of painful bone metastases"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain metastases (see
         <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">
          "Overview of the treatment of brain metastases"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Painful recurrences in the renal bed
        </p>
        <p>
        </p>
        <p>
         RT has been used as an adjuvant following nephrectomy in patients at high risk for local recurrence [
         <a href="#rid45">
          45-47
         </a>
         ], but its role in this setting remains unproven and is generally discouraged.
        </p>
        <p class="headingAnchor" id="H1835178498">
         <span class="h2">
          Brain metastases, treatment naïve
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with brain metastases should be treated with surgery and/or RT (preferably stereotactic radiosurgery) prior to initiation of systemic therapy with either vascular endothelial growth factor (VEGF) inhibitors or immunotherapy, due to the potential hemorrhagic nature of untreated tumors. We offer
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         and
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 3
         </a>
         ), rather than VEGF inhibitor therapy, for those with active or treated asymptomatic brain metastases not requiring steroids and with clinical indications for immunotherapy to treat extracranial systemic disease. Further details about the management of brain metastases in general are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5212.html" rel="external">
          "Overview of the treatment of brain metastases"
         </a>
         .)
        </p>
        <p>
         The optimal sequencing of immunotherapy in patients with brain metastases is evolving [
         <a href="#rid48">
          48-54
         </a>
         ]. The incidence of brain metastases among those with advanced RCC is approximately 10 percent [
         <a href="#rid55">
          55
         </a>
         ]. Median OS for these patients is between 4 and 35 months [
         <a href="#rid56">
          56
         </a>
         ]; graded prognostic assessments are available to estimate OS in individual patients and guide treatment options  (
         <a class="graphic graphic_table graphicRef129771" href="/z/d/graphic/129771.html" rel="external">
          table 4
         </a>
         ). However, most of the randomized trials evaluating immunotherapy in RCC have excluded patients with brain metastases. Most data come from small, phase II trials. In patients with asymptomatic treatment-naïve brain metastases, both immunotherapy and antiangiogenic therapies (such as
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ],
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         [
         <a href="#rid51">
          51
         </a>
         ], and
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         [
         <a href="#rid57">
          57
         </a>
         ]) have shown some intracranial efficacy, but durable response and safety in this setting have not been confirmed. In addition, some antiangiogenic agents are associated with an increased risk of intracerebral bleeding [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         The following trials have evaluated immunotherapy in this setting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one nonrandomized, open-label phase II trial (CheckMate 920), 28 patients with treatment-naïve RCC and asymptomatic untreated brain metastases received
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         for four cycles, followed by maintenance nivolumab [
         <a href="#rid53">
          53
         </a>
         ]. Responses were seen in 32 percent, with a median progression-free survival of nine months. Central nervous system immune-mediated adverse events included headache, myasthenia gravis, and tremor. Grade ≥3 immune-mediated toxicities included diarrhea, colitis, diabetic ketoacidosis, hepatitis, hypophysitis, and rash.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a separate, nonrandomized, open-label phase II trial (GETUG-AFU 26 NIVOREN), 73 patients with metastatic RCC and asymptomatic brain metastases received single-agent
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         after experiencing disease progression on antiangiogenic therapy [
         <a href="#rid52">
          52
         </a>
         ]. Approximately one-half had untreated brain metastases, while the other one-half had previously received brain RT, most frequently with stereotactic radiosurgery. Median follow-up was approximately two years. Among the 39 patients with untreated brain metastases, the intracranial objective response rate was 12 percent, and the median intracranial progression-free survival was 2.7 months. Approximately 70 percent required subsequent intracranial locoregional therapy (RT or surgery). In contrast, there were no objective responses seen in the 34 patients with prior RT. Grade ≥3 toxicities were reported in nine patients, with no treatment-related deaths.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1778596967">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1546633470">
         <span class="h2">
          von Hippel-Lindau disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with von Hippel-Lindau (VHL) disease are at risk for developing renal cell carcinoma (RCC) due to molecular alterations in the
         <em>
          VHL
         </em>
         gene. (See
         <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">
          "Molecular biology and pathogenesis of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p>
         Due to their unique biology, the treatment of patients with VHL-associated RCC may differ from those with sporadic RCC. For patients with locoregional disease, options for therapy include surveillance; nephron-sparing approaches; and
         <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">
          belzutifan
         </a>
         , a hypoxia-inducible factor-2 alpha inhibitor. Further details on the selection of therapy in patients with VHL-associated RCC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease", section on 'Renal cell carcinomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1311527675">
         <span class="h2">
          Other hereditary kidney cancer syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other hereditary syndromes are also associated with the development of RCC, such as polycystic kidney disease and hereditary leiomyomatosis and renal cell cancer (HLRCC). These and other hereditary syndromes associated with RCC are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4093482319">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">
          "Society guideline links: Cancer of the kidney and ureters"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056311611">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Localized disease
         </strong>
         – For patients with localized, resectable renal cell carcinoma (RCC), we recommend surgery as the primary treatment approach  (
         <a class="graphic graphic_algorithm graphicRef109427" href="/z/d/graphic/109427.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Radical nephrectomy has been the most widely used approach and remains the preferred procedure when there is evidence of invasion into the adrenal, renal vein, or perinephric fat. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Radical nephrectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Partial nephrectomy (either open or laparoscopic) is an alternative for smaller tumors and is particularly valuable in patients with bilateral or multiple lesions, those with inherited syndromes in whom there is an increased risk of an additional subsequent primary tumor, and those with impaired renal function. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Partial nephrectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For older adult patients and those with significant comorbid disease, ablative techniques (cryoablation, radiofrequency ablation) are an alternative. (See
         <a class="medical medical_review" href="/z/d/html/3001.html" rel="external">
          "Radiofrequency ablation, cryoablation, and other ablative techniques for renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Active surveillance may be an option for patients with small asymptomatic lesions. (See
         <a class="local">
          'Active surveillance in nonsurgical candidates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjuvant therapy for locoregional disease
         </strong>
         – For patients with intermediate-high and high-risk locoregional clear cell RCC treated with nephrectomy, particularly those with an estimated risk of recurrence at five years of ≥30 percent (
         <a class="calc calc_professional" href="/z/d/html/140668.html" rel="external">
          calculator 1
         </a>
         ), we suggest one year of adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ), as this approach improved disease-free survival (DFS). However, observation remains a reasonable alternative in this patient population, pending further follow-up confirming long-term DFS and overall survival (OS) benefit. (See
         <a class="local">
          'Adjuvant therapy for locoregional disease'
         </a>
         above and
         <a class="local">
          'Pembrolizumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For those with lower-risk disease (estimated risk of recurrence at five years &lt;30 percent) or those who do not meet the pathologic criteria for intermediate-high or high risk of disease recurrence, we offer active surveillance after nephrectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advanced or metastatic clear cell RCC
         </strong>
         – Most treatment-naïve patients with advanced or metastatic clear cell RCC receive systemic therapy with immunotherapy and/or molecularly targeted therapy  (
         <a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">
          algorithm 2
         </a>
         ). Systemic therapy is initiated promptly in most patients with substantial disease burden. Active surveillance may be offered to asymptomatic patients with favorable-risk disease  (
         <a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">
          table 2
         </a>
         ) and limited disease burden to determine the pace of disease. Clinical trials are encouraged if available. (See
         <a class="local">
          'General treatment approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Active surveillance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preferred options for immunotherapy-based combination regimens include
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 3
         </a>
         ),
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         , nivolumab plus
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         plus pembrolizumab. Other available options include
         <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">
          avelumab
         </a>
         plus axitinib. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Selection of initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are ineligible for immunotherapy-based combinations, we offer antiangiogenic therapy with inhibitors of the vascular endothelial growth factor (VEGF) pathway. (See
         <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">
          "Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Preferred VEGFR inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who relapse on immunotherapy and/or molecularly targeted agents, the choice of subsequent therapy is dependent on prior therapy received. (See
         <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">
          "Systemic therapy of advanced clear cell renal carcinoma", section on 'Subsequent therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjuvant therapy after metastasectomy
         </strong>
         –
         <strong>
         </strong>
         For patients with metastatic clear cell RCC treated with nephrectomy and fully resected oligometastatic disease, we suggest one year of adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Adjuvant therapy after metastasectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brain metastases
         </strong>
         – For patients with treatment-naïve brain metastases, we offer surgery and/or radiation therapy prior to initiation of antiangiogenic therapy and/or immunotherapy, due to the potential hemorrhagic nature of untreated tumors.
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          Nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">
          table 3
         </a>
         ) remains an option for patients with active or treated asymptomatic brain metastases and with clinical indications for immunotherapy to treat extracranial disease, but the efficacy and safety of this approach remain investigational. (See
         <a class="local">
          'Brain metastases, treatment naïve'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytoreductive nephrectomy
         </strong>
         – Removal of the primary tumor (cytoreductive or debulking nephrectomy) may be indicated prior to initiating systemic therapy in select patients (eg, good performance status, 75 percent debulking possible, no symptomatic metastatic disease). (See
         <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">
          "Role of surgery in patients with metastatic renal cell carcinoma", section on 'Cytoreductive nephrectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Non-clear cell RCC
         </strong>
         – The treatment approach to patients with metastatic non-clear cell RCCs is varied and tailored to the histologic subtype and pathologic and molecular features of the tumor. (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal cell carcinoma with sarcomatoid features
         </strong>
         – Renal cell carcinoma with sarcomatoid features, or sarcomatoid RCC, can be seen in both clear cell and non-clear cell histologies. Advanced or metastatic sarcomatoid RCC is responsive to immunotherapy-based regimens. (See
         <a class="medical medical_review" href="/z/d/html/128561.html" rel="external">
          "Renal cell carcinoma with sarcomatoid features"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Santos Arrontes D, Fernández Aceñero MJ, García González JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 2008; 179:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome. Urology 2004; 64:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. Cancer 2004; 100:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rendon RA, Stanietzky N, Panzarella T, et al. The natural history of small renal masses. J Urol 2000; 164:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wehle MJ, Thiel DD, Petrou SP, et al. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 2004; 64:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybicki FJ, Shu KM, Cibas ES, et al. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 2003; 180:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021; 385:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22:3316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leibovich BC, Lohse CM, Cheville JC, et al. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. Eur Urol 2018; 73:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oza B, Eisen T, Frangou E, et al. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. J Clin Oncol 2022; 40:1772.
          </a>
         </li>
         <li class="breakAll">
          Pembrolizumab: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf (Accessed on April 12, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med 2016; 375:2246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387:2008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mamtani R, Wang XV, Gyawali B, et al. Association between age and sex and mortality after adjuvant therapy for renal cancer. Cancer 2019; 125:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol 2017; 35:3916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018; 29:2371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisen T, Frangou E, Oza B, et al. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J Clin Oncol 2020; 38:4064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2022; 400:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allaf M, Kim SE, Harshman LC, et al. Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol 2022; 33;7S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 2023; 401:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Russo P, Grunwald V, et al. Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial. J Clin Oncol 2023; 41;16S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Russo P, Haas N, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021; 79:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamie K, Donin NM, Klöpfer P, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan CW, Tangen CM, Heath EI, et al. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2023; 402:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powles T, Albiges L, Staehler M, et al. Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. Eur Urol 2018; 73:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 2020; 126:4156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkins MB. Management of advanced renal cancer. Kidney Int 2005; 67:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KT, Manola JB, Pins M, et al. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 2015; 33:2384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:2765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 2010; 28:5017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev 1988; 15:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stahl M, Wilke H, Schmoll HJ, et al. A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 1992; 3:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appleman LJ, Puligandla M, Pal SK, et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). J Clin Oncol 2019; 37S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Procopio G, Apollonio G, Cognetti F, et al. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Eur Urol Oncol 2019; 2:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang C, Msaouel P, Hara K, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol 2021; 22:1732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rafla S. Renal cell carcinoma. Natural history and results of treatment. Cancer 1970; 25:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finney R. The value of radiotherapy in the treatment of hypernephroma--a clinical trial. Br J Urol 1973; 45:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chevreau C, Ravaud A, Escudier B, et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 2014; 12:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008; 53:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010; 21:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol 2019; 37:2008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emamekhoo H, Olsen MR, Carthon BC, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer 2022; 128:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrer EJ, Gurewitz J, Bernstein K, et al. Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study. Cancer 2022; 128:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 2017; 19:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sperduto PW, Mesko S, Li J, et al. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol 2020; 38:3773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch L, Martinez Chanza N, Farah S, et al. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol 2021; 7:1815.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15719 Version 97.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18221956" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15533476" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7480724" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Small renal parenchymal neoplasms: further observations on growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14770429" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The natural history of incidentally detected small renal masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10992354" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The natural history of small renal masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15245934" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12704038" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34407342" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36055304" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12454113" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15310775" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29398265" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35213214" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35213214" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27718781" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26969090" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30620389" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association between age and sex and mortality after adjuvant therapy for renal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28902533" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30346481" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33052759" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36099926" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36774933" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33461782" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27787547" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37524096" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23312463" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29562145" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29223605" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26406148" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32673417" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840065" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management of advanced renal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26077237" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24297950" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25049330" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26406150" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20975069" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Another step toward the cure of metastatic renal cell carcinoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8493752" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cytotoxic chemotherapy for advanced renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2974757" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1606089" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31542243" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34717797" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5410313" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Renal cell carcinoma. Natural history and results of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4712834" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The value of radiotherapy in the treatment of hypernephroma--a clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3553111" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24268852" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20862748" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17825982" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19850637" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31194611" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34784056" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35077586" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28444227" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32931399" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34673916" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
